|
市場調查報告書
產品簡介:老年癡呆症 - 在治療範例中帶來革命的免疫療法
Product Profiles: Alzheimer's Disease - Immunotherapies can revolutionize treatment paradigm
| 出版商 |
Datamonitor |
| 出版日期 |
2011年11月 |
商品編碼 |
229432 |
| 內容資訊 |
英文 Pages: 150 |
| 價格 |
|
|
產品簡介:老年癡呆症 - 在治療範例中帶來革命的免疫療法 是由出版商Datamonitor在2011年11月所出版的。
這份英文市場調查報告書包含Pages: 150 價格從美金11400起跳。
本報告提供老年癡呆症的治療藥物市場相關調查，主要上市產品、開發管道產品的簡介、開發概要、臨床資料、SWOT分析、產品定位、臨床、商業性魅力相關分析，包含開發中的病情修飾藥簡介，為您概述為以下內容。
摘要整理
概要
產品概要
上市產品簡介
- Aricept (donepezil; Eisai/Pfizer)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
- Exelon (rivastigmine; Novartis)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
- Razadyne (galantamine; Johnson & Johnson/Shire)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
- Namenda (memantine; Forest/Merz/Lundbeck)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
開發中產品簡介
- Bapineuzumab (Johnson & Johnson/Pfizer)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
- Solanezumab (LY2062430; Eli Lilly)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
- Gammagard (intravenous immunoglobulin; Baxter)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
- Aricept patch (transdermal donepezil; Eisai/帝國製藥)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
- SB-742457 (GlaxoSmithKline)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
- 針對老年癡呆病所開發的其他主要病情修飾藥
- 針對老年癡呆病所開發的其他主要對症性藥物
參考文獻
附錄A - 調查資訊
附錄B
圖表
Description
Introduction
The beta-amyloid hypothesis has so far failed to deliver a viable candidate, contributing to an absence of new market entrants over the past decade. However, given the weight of candidates with disease-modifying potential in the pipeline, new drugs are expected to emerge that will satisfy one of the biggest unmet needs in the industry - a treatment that slows Alzheimer's disease neurodegeneration.
Features and benefits
- Understand Datamonitor's independent appraisal of marketed brands and key pipeline agents indicated for treating Alzheimer's disease.
- Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes.
- Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
- Understand how marketed brands are positioned in the Alzheimer's disease treatment algorithm.
- Determine to what extent future therapies satisfy the main clinical unmet needs in Alzheimer's disease treatment.
Highlights
- Datamonitor's physician survey reveals that Aricept finds widespread use across all lines of therapy and severities, from mild cognitive impairment to severe Alzheimer's disease. However, Eisai faces a steep decline in revenues as generic donepezil take hold in the US, marketed competition heightens in Japan, and European patents near expiry.
- Bapineuzumab and solanezumab have the potential to revolutionize Alzheimer's disease treatment and become future market leaders. However, each program carries a caveat. J&J/Pfizer are relying on post-hoc analyses of bapineuzumab in a subpopulation while Lilly is betting on solanezumab's Phase II biomarker effect translating into tangible benefits.
- A precedent already exists for neurotransmitter mechanisms, ensuring a higher likelihood of navigating through clinical trials. Late-stage symptomatic drugs include Eisai's Aricept patch and GSK's 5-HT6 receptor agonist SB-742457, although the potential rewards on offer for these candidates are lower than for the immunotherapies.
Your key questions answered
- How do drugs in development compare to the current gold-standard treatment for Alzheimer's disease?
- Which are the most likely drugs to emerge from the pipeline and how will they impact the way Alzheimer's disease is treated?
- How are marketed brands positioned in the Alzheimer's disease treatment algorithm?
- What are the comparative strengths and weaknesses of the key Alzheimer's disease brands and pipeline candidates?
TOC
Executive Summary
- Strategic scoping and focus
- Datamonitor key findings
- Related reports
OVERVIEW
PRODUCT OVERVIEW
MARKETED PRODUCT PROFILES
- Aricept (donepezil; Eisai/Pfizer)
- Drug profile
- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness
- Exelon (rivastigmine; Novartis)
- Drug profile
- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness
- Razadyne (galantamine; Johnson & Johnson/Shire)
- Drug profile
- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness
- Namenda (memantine; Forest/Merz/Lundbeck)
- Drug profile
- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness
PIPELINE PRODUCT PROFILES
- Bapineuzumab (Johnson & Johnson/Pfizer)
- Drug profile
- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness
- Solanezumab (LY2062430; Eli Lilly)
- Drug profile
- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness
- Gammagard (intravenous immunoglobulin; Baxter)
- Drug profile
- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness
- Aricept patch (transdermal donepezil; Eisai/Teikoku Seiyaku)
- Drug profile
- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness
- SB-742457 (GlaxoSmithKline)
- Drug profile
- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness
- Other key disease-modifying drugs in development for Alzheimer's disease
- ACC-001 (conjugate beta-amyloid vaccine; Johnson & Johnson/Pfizer)
- AD02 (beta-amyloid vaccine; GlaxoSmithKline/Affiris)
- Avagacestat (BMS-708163; Bristol-Myers Squibb)
- CAD106 (beta-amyloid vaccine; Novartis/Cytos Biotechnology)
- CERE-110 (AAV2-NGF; Ceregene)
- CHF5074 (Chiesi Pharmaceuticals)
- Crenezumab (R7412/MABT5102A; Roche/AC Immune)
- Davunetide (AL-108; Allon Therapeutics)
- ELND005 (scyllo-inositol; Elan)
- EHT 0202 (etazolate; ExonHit Therapeutics)
- Gantenerumab (R1450; Roche/MorphoSys)
- Masitinib (AB1010; AB Science)
- NIC5-15 (Humanetics)
- Nypta (tideglusib; Noscira)
- Octagam (intravenous immunoglobulin; Octapharma)
- PF-04494700 (Pfizer/TransTech Pharma)
- PBT2 (Prana Biotechnology)
- Rember (methylthioninium chloride; TauRx Pharmaceuticals)
- T-817MA (Toyama Chemical)
- Other key symptomatic drugs in development for Alzheimer's disease
- ABT-288 (Abbott Laboratories)
- Dimebon (latrepirdine; Pfizer/Medivation)
- EVP-6124 (EnVivo Pharmaceuticals)
- GSK239512 (GlaxoSmithKline)
- Ispronicline (AZD3480; AstraZeneca/Targacept)
- Lu AE58054 (Lundbeck)
BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports
APPENDIX A - SURVEY INFORMATION
- Physician research methodology
- Physician sample breakdown
- The survey questionnaire
- Screener
- Section 10: Alzheimer's disease regimens
- Section 11: Treated disease stages
- Section 12: Treatment flow - mild cognitive impairment due to Alzheimer's disease
- Section 13: Treatment flow - mild Alzheimer's disease
- Section 14: Treatment flow - moderate Alzheimer's disease
- Section 15: Treatment flow - severe Alzheimer's disease
APPENDIX B
- PharmaVitae Explorer database
- Datamonitor drug assessment scorecard
- Contributing experts
- Conferences attended
- Report methodology
|
